Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: DCT002
MIFTS: 58

Ductal Carcinoma in Situ

Categories: Cancer diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Ductal Carcinoma in Situ

About this section

MalaCards integrated aliases for Ductal Carcinoma in Situ:

Name: Ductal Carcinoma in Situ 12 30 15 17
Noninfiltrating Intraductal Carcinoma 74

Classifications:

MalaCards categories:
Global: Cancer diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:0060074
UMLS 74 C0007124
Sources

Summaries for Ductal Carcinoma in Situ

About this section
Disease Ontology : 12 A breast carcinoma in situ that is characterized by being non-invasive, not having spread outside of the duct into the surrounding breast tissue, has material basis in abnormally proliferating cells, derives from epithelial cells.

MalaCards based summary : Ductal Carcinoma in Situ, also known as noninfiltrating intraductal carcinoma, is related to comedo carcinoma and in situ carcinoma. An important gene associated with Ductal Carcinoma in Situ is AKT1 (AKT Serine/Threonine Kinase 1), and among its related pathways/superpathways are ERK Signaling and GPCR Pathway. The drugs Doxorubicin and Epirubicin have been mentioned in the context of this disorder. Affiliated tissues include breast, lymph node and skin, and related phenotypes are Increased cell death HMECs cells and cellular

Wikipedia : 77 Ductal carcinoma in situ (DCIS), also known as intraductal carcinoma, is a pre-cancerous or non-invasive... more...

Sources

Related Diseases for Ductal Carcinoma in Situ

About this section

Diseases related to Ductal Carcinoma in Situ via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 277)
# Related Disease Score Top Affiliating Genes
1 comedo carcinoma 32.9 ERBB2 ESR1
2 in situ carcinoma 31.3 BRCA1 CDH1 EGFR ERBB2 ESR1 KRT14
3 breast reconstruction 31.2 BRCA1 BRCA2
4 gynecomastia 30.6 AR CYP19A1 ESR1 PGR
5 mammographic density 30.5 CYP19A1 ESR1 PGR
6 lobular neoplasia 30.3 BRCA1 CDH1 ERBB2 ESR1 MUC1
7 papillary carcinoma 30.2 CDH1 ERBB2 MUC1 PGR
8 bilateral breast cancer 30.1 BRCA1 BRCA2 ERBB2 PGR
9 papilloma 30.0 CCND1 KRT14 KRT5 KRT8 TP53
10 breast fibroadenoma 30.0 CYP19A1 ERBB2 ESR1 KRT14 KRT8 PGR
11 microglandular adenosis 29.6 EGFR ERBB2 PGR PIP TP53
12 breast disease 29.5 BRCA1 BRCA2 CYP19A1 ERBB2 ESR1 KRT5
13 mammary paget's disease 29.4 EGFR ERBB2 ESR1 KRT8 MUC1 PGR
14 breast ductal carcinoma 29.3 AR BRCA1 CCND1 CDH1 EGFR ERBB2
15 adenocarcinoma 29.1 AKT1 CCND1 CDH1 EGFR ERBB2 MUC1
16 squamous cell carcinoma 28.7 AKT1 CCND1 CDH1 EGFR ERBB2 MUC1
17 ovarian cancer 28.5 AKT1 BRCA1 BRCA2 CCND1 CDH1 EGFR
18 breast cancer 26.7 AKT1 AR BRCA1 BRCA2 CCND1 CDH1
19 breast apocrine carcinoma in situ 11.3
20 intracystic papillary adenoma 10.6 ERBB2 PGR
21 scirrhous adenocarcinoma 10.6 ERBB2 PGR
22 vestibular gland benign neoplasm 10.6 ESR1 PGR
23 vulvar benign neoplasm 10.6 ESR1 PGR
24 breast apocrine carcinoma 10.6 ERBB2 PGR
25 trigonitis 10.6 ESR1 PGR
26 vulvar syringoma 10.6 ESR1 PGR
27 lung leiomyoma 10.6 ESR1 PGR
28 vulvar leiomyoma 10.6 ESR1 PGR
29 bartholin's gland adenoma 10.6 ESR1 PGR
30 gastric papillary adenocarcinoma 10.6 ERBB2 TP53
31 endometrium carcinoma in situ 10.6 PGR TP53
32 breast intraductal proliferative lesion 10.5 EGFR ERBB2
33 rare adenocarcinoma of the breast 10.5 AKT1 TP53
34 breast papillomatosis 10.5 CCND1 ERBB2
35 brain ependymoma 10.5 EGFR TP53
36 protoplasmic astrocytoma 10.5 PTGS2 TP53
37 hereditary site-specific ovarian cancer syndrome 10.5 BRCA1 BRCA2
38 cerebral convexity meningioma 10.5 CDH1 TP53
39 mixed cell type cancer 10.4 ERBB2 PGR TP53
40 sulfite oxidase deficiency due to molybdenum cofactor deficiency 10.4
41 adenosarcoma 10.4 ESR1 PGR TP53
42 breast mucoepidermoid carcinoma 10.4 MUC1 PGR
43 supratentorial cancer 10.4 AKT1 EGFR TP53
44 central nervous system cancer 10.4 AKT1 EGFR TP53
45 cerebrum cancer 10.4 AKT1 EGFR TP53
46 glassy cell carcinoma of the cervix 10.4 ERBB2 ESR1 PGR
47 esophagus adenocarcinoma 10.4 ERBB2 PTGS2 TP53
48 barrett's adenocarcinoma 10.4 ERBB2 PTGS2 TP53
49 leukocyte disease 10.4 AKT1 CCND1 TP53
50 penile cancer 10.4 CCND1 EGFR TP53

Graphical network of the top 20 diseases related to Ductal Carcinoma in Situ:



Diseases related to Ductal Carcinoma in Situ
Sources

Symptoms & Phenotypes for Ductal Carcinoma in Situ

About this section

GenomeRNAi Phenotypes related to Ductal Carcinoma in Situ according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased cell death HMECs cells GR00103-A-0 9.1 BRCA1 EGFR PGR PIP S100A7 TP53

MGI Mouse Phenotypes related to Ductal Carcinoma in Situ:

47 (show all 26)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.49 AKT1 AR BRCA1 BRCA2 CCND1 CDH1
2 growth/size/body region MP:0005378 10.48 AKT1 AR BRCA1 BRCA2 CCND1 CDH1
3 digestive/alimentary MP:0005381 10.47 AR BRCA1 BRCA2 CCND1 CDH1 CYP19A1
4 cardiovascular system MP:0005385 10.46 AKT1 AR BRCA1 CCND1 CDH1 CYP19A1
5 endocrine/exocrine gland MP:0005379 10.46 AKT1 AR BRCA1 BRCA2 CCND1 CDH1
6 homeostasis/metabolism MP:0005376 10.46 AKT1 AR BRCA1 BRCA2 CCND1 CDH1
7 hematopoietic system MP:0005397 10.44 AKT1 AR BRCA1 BRCA2 CCND1 CLDN7
8 integument MP:0010771 10.44 AKT1 AR BRCA1 BRCA2 CCND1 CDH1
9 immune system MP:0005387 10.42 AKT1 AR BRCA1 BRCA2 CCND1 CDH1
10 behavior/neurological MP:0005386 10.4 AKT1 AR BRCA1 BRCA2 CCND1 CYP19A1
11 mortality/aging MP:0010768 10.4 AKT1 AR BRCA1 BRCA2 CCND1 CDH1
12 embryo MP:0005380 10.37 AKT1 AR BRCA1 BRCA2 CDH1 EGFR
13 adipose tissue MP:0005375 10.28 AKT1 AR BRCA1 CYP19A1 EGFR ESR1
14 neoplasm MP:0002006 10.27 AKT1 AR BRCA1 BRCA2 CCND1 CDH1
15 limbs/digits/tail MP:0005371 10.18 AR BRCA1 BRCA2 EGFR ERBB2 ESR1
16 muscle MP:0005369 10.18 AKT1 AR BRCA1 CYP19A1 EGFR ERBB2
17 normal MP:0002873 10.18 AKT1 AR BRCA1 BRCA2 CCND1 CDH1
18 nervous system MP:0003631 10.17 AKT1 AR BRCA1 BRCA2 CCND1 CYP19A1
19 craniofacial MP:0005382 10.15 AR CCND1 EGFR ERBB2 KRT14 KRT5
20 liver/biliary system MP:0005370 10.11 AKT1 AR CYP19A1 EGFR ESR1 KRT8
21 reproductive system MP:0005389 10.06 AKT1 AR BRCA1 BRCA2 CCND1 CDH1
22 no phenotypic analysis MP:0003012 9.95 CDH1 EGFR ESR1 KRT5 PGR PTGS2
23 renal/urinary system MP:0005367 9.86 AR BRCA1 CLDN7 CYP19A1 EGFR ESR1
24 pigmentation MP:0001186 9.8 AR BRCA1 CYP19A1 EGFR KRT14 TP53
25 respiratory system MP:0005388 9.61 AKT1 BRCA1 CCND1 EGFR ERBB2 ESR1
26 skeleton MP:0005390 9.4 AKT1 AR BRCA1 BRCA2 CCND1 CYP19A1
Sources

Drugs & Therapeutics for Ductal Carcinoma in Situ

About this section

Drugs for Ductal Carcinoma in Situ (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 227)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
2
Epirubicin Approved Phase 4,Phase 3,Phase 2 56420-45-2 41867
3
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2 6055-19-2, 50-18-0 2907
4
Docetaxel Approved, Investigational Phase 4,Phase 3,Phase 2 114977-28-5 148124
5
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 31703
6 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2
10 Immunosuppressive Agents Phase 4,Phase 3,Phase 2
11 Immunologic Factors Phase 4,Phase 3,Phase 1,Phase 2
12 Alkylating Agents Phase 4,Phase 3,Phase 2
13 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1
14 Antirheumatic Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
15
Tamoxifen Approved Phase 3,Phase 2,Phase 1,Not Applicable 10540-29-1 2733526
16
Anastrozole Approved, Investigational Phase 3,Phase 2 120511-73-1 2187
17
Sodium Citrate Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 68-04-2
18
Cisplatin Approved Phase 2, Phase 3 15663-27-1 441203 84093 2767
19
Carboplatin Approved Phase 3,Phase 2 41575-94-4 38904 10339178 498142
20
Progesterone Approved, Vet_approved Phase 3,Phase 2,Early Phase 1,Not Applicable 57-83-0 5994
21
Trastuzumab Approved, Investigational Phase 3,Phase 1,Phase 2,Not Applicable 180288-69-1 9903
22
Risedronate Approved, Investigational Phase 3 105462-24-6 5245
23
mometasone furoate Approved, Investigational, Vet_approved Phase 3 83919-23-7
24
Medroxyprogesterone acetate Approved, Investigational Phase 3 71-58-9
25
leucovorin Approved Phase 3 58-05-9 6006 143
26
Fluorouracil Approved Phase 3,Phase 2 51-21-8 3385
27
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
28
Exemestane Approved, Investigational Phase 3,Phase 2 107868-30-4 60198
29
Paclitaxel Approved, Vet_approved Phase 2, Phase 3,Phase 3,Phase 1 33069-62-4 36314
30
Pertuzumab Approved Phase 3,Phase 1,Phase 2 380610-27-5, 145040-37-5 2540
31
Letrozole Approved, Investigational Phase 3,Phase 2,Not Applicable 112809-51-5 3902
32
Oxybutynin Approved, Investigational Phase 3 5633-20-5 4634
33
Olaparib Approved Phase 2, Phase 3 763113-22-0 23725625
34
Metformin Approved Phase 3 657-24-9 14219 4091
35
Sargramostim Approved, Investigational Phase 3,Phase 2,Phase 1 123774-72-1, 83869-56-1
36
Lenograstim Approved, Investigational Phase 3 135968-09-1
37
Pembrolizumab Approved Phase 3,Early Phase 1 1374853-91-4
38
Adenosine Approved, Investigational Phase 3 58-61-7 60961
39
Bevacizumab Approved, Investigational Phase 3,Phase 2 216974-75-3
40
Leuprolide Approved, Investigational Phase 3 53714-56-0 657181 3911
41
Capecitabine Approved, Investigational Phase 3,Phase 2 154361-50-9 60953
42
Citric Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 77-92-9 311
43
Calcium Approved, Nutraceutical Phase 3,Phase 2,Phase 1,Not Applicable 7440-70-2 271
44
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
45
Lapatinib Approved March 2007, Investigational Phase 3,Phase 2,Not Applicable 388082-78-8, 231277-92-2 208908 9941095
46 Antineoplastic Agents, Hormonal Phase 3,Phase 2,Phase 1,Not Applicable
47 Hormone Antagonists Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
48 Selective Estrogen Receptor Modulators Phase 3,Phase 2,Phase 1,Not Applicable
49 Citrate Phase 3,Phase 2,Phase 1,Not Applicable
50 Estrogen Receptor Modulators Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 253)
# Name Status NCT ID Phase Drugs
1 Phase IV Trial to Evaluate Breast Brachytherapy Using the Mammosite-Ml® Completed NCT01448447 Phase 4
2 Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer Completed NCT00742222 Phase 4
3 Neoadjuvant Chemotherapy With or Without Huaier Granule in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery Recruiting NCT02627248 Phase 4 Huaier Granule;Epirubicin;Docetaxel;Cyclophosphamide
4 An Open-label, Multi-center Phase â…£ Trial to Evaluate the Efficacy and Safety of Sequential Neoadjuvant Chemotherapy With Docetaxel(Monotaxel®) After Doxorubicin Plus Cyclophosphamide Combination Chemotherapy in Locally Advanced Breast Cancer Completed NCT01660542 Phase 4 Neoadjuvant Chemotherapy with Docetaxel
5 Spect Analysis of Cardiac Perfusion Changes After Whole Breast/Chest Wall Radiation Therapy With Active Breathing Coordinator Unknown status NCT00321048 Phase 3
6 Evaluation of the Diagnostic Performance of MRI±Biopsy to Optimize Resection of Ductal Carcinoma In Situ (DCIS) Breast Cancer Completed NCT01112254 Phase 3
7 Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Active, not recruiting NCT00769379 Phase 3
8 Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy Completed NCT00053898 Phase 3 anastrozole;tamoxifen citrate
9 Breast-Conserving Surgery and Whole-Breast Radiation Therapy With or Without Additional Radiation Therapy to the Tumor in Treating Women With Ductal Carcinoma in Situ (BONBIS) Active, not recruiting NCT00907868 Phase 3
10 Radiation Doses and Fractionation Schedules in Non-low Risk Ductal Carcinoma In Situ (DCIS) of the Breast Active, not recruiting NCT00470236 Phase 3
11 Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ Active, not recruiting NCT00072462 Phase 3 tamoxifen citrate;Anastrozole
12 Radiation Therapy With or Without Optional Tamoxifen in Treating Women With Ductal Carcinoma in Situ Active, not recruiting NCT00003857 Phase 3 tamoxifen citrate
13 Risedronate in Improving Bone Mineral Density and Bone Health in Postmenopausal Women With Ductal Carcinoma In Situ Enrolled in Clinical Trial CRUK-IBIS-II-DCIS Withdrawn NCT00324714 Phase 3 risedronate sodium
14 Genetic Counseling or Usual Care in Helping Women With Newly Diagnosed Ductal Carcinoma In Situ or Stage I, Stage II, or Stage IIIA Breast Cancer Make Treatment Decisions Completed NCT00262899 Phase 3
15 Mometasone Furoate in Preventing Radiation Dermatitis in Patients Undergoing Radiation Therapy to the Breast or Chest Wall for Invasive Breast Cancer or Ductal Carcinoma in Situ Completed NCT00438659 Phase 3 mometasone furoate
16 APBI Versus EBRT Therapy After Breast Conserving Surgery for Low-risk Breast Cancer Active, not recruiting NCT00402519 Phase 3
17 Management of Low-risk DCIS Recruiting NCT02492607 Phase 3
18 Intraoperative Gamma Camera for Breast Cancer Surgery Completed NCT00757302 Phase 3
19 Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer Completed NCT00026286 Phase 3 conjugated estrogens;medroxyprogesterone
20 Study of Docetaxel in Breast Cancer Patients Completed NCT00174707 Phase 3 epidoxorubicine, ciclophosphamide, methotrexate, fluorouracile;epidoxorubicine, docetaxel, ciclophosphamide, methotrexate, fluorouracile;epidoxorubicine, docetaxel, cyclophosphamide
21 S9630, Medroxyprogesterone in Treating Women With Breast Cancer Completed NCT00002920 Phase 3 medroxyprogesterone;tamoxifen citrate
22 The LightPath® and 68Ga-RM2 in Breast Cancer Study Not yet recruiting NCT03731026 Phase 3 68Ga-RM2
23 Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer Completed NCT00374322 Phase 3 lapatinib
24 Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer Completed NCT00038467 Phase 3 Tamoxifen;Exemestane
25 Trial of Low Dose Tamoxifen in Women With Breast Intraepithelial Neoplasia Active, not recruiting NCT01357772 Phase 3 Tamoxifen;placebo
26 Apatinib in Neoadjuvant Therapy for Patients With Breast Cancer Enrolling by invitation NCT03580395 Phase 2, Phase 3 Apatinib;paclitaxel;cisplatin
27 Shave Margins vs. Standard Partial Mastectomy in Breast Cancer Patients Active, not recruiting NCT02772731 Phase 3
28 A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer Active, not recruiting NCT01358877 Phase 3 5-Fluorouracil;Carboplatin;Cyclophosphamide;Docetaxel;Doxorubicin;Epirubicin;Paclitaxel;Pertuzumab;Placebo;Trastuzumab
29 CONcurrent vs SEqueNTial Adjuvant Treatments in Early Breast Cancer Recruiting NCT02918084 Phase 3 Anastrozole or Letrozole or Exemestane;Anastrozole or Letrozole or Exemestane
30 Oxybutynin Chloride in Managing Hot Flashes Active, not recruiting NCT02961790 Phase 3 Oxybutynin Chloride
31 Platinum and Polyadenosine 5'Diphosphoribose Polymerisation (PARP) Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer (TNBC) and/or Germline BRCA (gBRCA) Positive Breast Cancer Recruiting NCT03150576 Phase 2, Phase 3 Olaparib;Paclitaxel and Carboplatin
32 Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer Recruiting NCT01905046 Phase 3 metformin hydrochloride
33 A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Active, not recruiting NCT01566721 Phase 3 Herceptin
34 Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522) Active, not recruiting NCT03036488 Phase 3 Carboplatin;Paclitaxel;Doxorubicin;Epirubicin;Cyclophosphamide;Placebo
35 Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer Active, not recruiting NCT00878709 Phase 3 neratinib
36 Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane Completed NCT00036270 Phase 3 exemestane (Aromasin);tamoxifen + exemestane
37 A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer Active, not recruiting NCT01966471 Phase 3 Trastuzumab Emtansine;Trastuzumab;Pertuzumab;Paclitaxel;Epirubicin;Doxorubicin;Docetaxel;Cyclophosphamide;5-Fluorouracil
38 Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Active, not recruiting NCT01272037 Phase 3 Anastrozole;Exemestane;Letrozole;Systemic Chemotherapy;Tamoxifen Citrate
39 BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer Completed NCT00528567 Phase 3 Bevacizumab;Standard adjuvant chemotherapy
40 Neoadjuvant Chemo-endocrine Therapy Versus Chemotherapy Alone in ER-positive, HER2-negative Breast Cancer Completed NCT02980965 Phase 3 letrozole, leuprorelin, fluorouracil, epirubicin, cyclophosphamide, docetaxel;fluorouracil, epirubicin, cyclophosphamide, docetaxel
41 A Study of the Addition of Metronomic Capecitabine to Standard Adjuvant Therapy in High Risk HER2+ BC paTients Recruiting NCT03561740 Phase 3 capecitabine
42 Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery Active, not recruiting NCT01349322 Phase 3
43 A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE) Active, not recruiting NCT01772472 Phase 3 trastuzumab;trastuzumab emtansine
44 Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women Completed NCT00003906 Phase 3 Raloxifene;Tamoxifen
45 Study Of Intraductal Carboplatin In Women With Ductal Carcinoma In Situ (DCIS) Unknown status NCT00669747 Phase 2 Carboplatin i.d. Days 1 & 15;Carboplatin i.d. Day 1; Normal Saline i.d. Day 15;Normal Saline
46 Adjuvant Radiation Therapy Compared With Observation After Surgery in Treating Women With Estrogen Receptor Positive or Progesterone Receptor Positive Ductal Carcinoma In Situ of the Breast Who Are Receiving Tamoxifen or Anastrozole Unknown status NCT00077168 Phase 2 anastrozole;tamoxifen citrate
47 Dose Optimization for Pulsed-dose-rate (PDR)/High-dose-rate (HDR) Brachytherapy Alone for Early Breast Cancer Unknown status NCT01175694 Phase 2
48 Cisplatin-monotherapy in the Treatment of BRCA1 Positive Breast Cancer Patients in Poland Unknown status NCT01630226 Phase 2 Neoadjuvant Cisplatin Chemotherapy
49 Docosahexaenoic Acid in Preventing Recurrence in Breast Cancer Survivors Unknown status NCT01849250 Phase 2 Docosahexaenoic Acid
50 Gefitinib Followed By Surgery in Treating Women With Ductal Carcinoma In Situ of the Breast Terminated NCT00082667 Phase 2 gefitinib

Search NIH Clinical Center for Ductal Carcinoma in Situ

Sources

Genetic Tests for Ductal Carcinoma in Situ

About this section

Genetic tests related to Ductal Carcinoma in Situ:

# Genetic test Affiliating Genes
1 Ductal Carcinoma in Situ 30
Sources

Anatomical Context for Ductal Carcinoma in Situ

About this section

MalaCards organs/tissues related to Ductal Carcinoma in Situ:

42
Breast, Lymph Node, Skin, Testes, Bone, Liver, Prostate
Sources

Publications for Ductal Carcinoma in Situ

About this section

Articles related to Ductal Carcinoma in Situ:

(show top 50) (show all 2231)
# Title Authors Year
1
"Development and validation of algorithms to differentiate ductal carcinoma in situ from invasive breast cancer within administrative claims data" by Hirth JM, Hatch SS, Lin Y, Giordano SH, Silva HC, Kuo Y. ( 30875106 )
2019
2
PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer. ( 30844755 )
2019
3
Influence of ductal carcinoma in situ on the outcome of invasive breast cancer. A prospective cohort study. ( 30738200 )
2019
4
Parity Differently Affects the Breast Cancer Specific Survival from Ductal Carcinoma In Situ to Invasive Cancer: A Registry-Based Retrospective Study from Korea. ( 30728717 )
2019
5
Risk factors for Luminal A ductal carcinoma in situ (DCIS) and invasive breast cancer in the Carolina Breast Cancer Study. ( 30682163 )
2019
6
Sentinel lymph node biopsy in patients affected by breast ductal carcinoma in situ with and without microinvasion: Retrospective observational study. ( 30608397 )
2019
7
Association of Magnetic Resonance Imaging and a 12-Gene Expression Assay With Breast Ductal Carcinoma In Situ Treatment. ( 30653209 )
2019
8
MNK1/NODAL signaling promotes invasive progression of breast ductal carcinoma in situ. ( 30659022 )
2019
9
Identification of aberrant gene expression during breast ductal carcinoma in situ progression to invasive ductal carcinoma. ( 30712460 )
2019
10
The prognostic significance of lysosomal protective protein (Cathepsin A) in breast ductal carcinoma in situ. ( 30725481 )
2019
11
Evaluating the frequency of upgrade to malignancy following surgical excision of high-risk breast lesions and ductal carcinoma in situ identified by core needle biopsy. ( 30461129 )
2019
12
Breast conserving surgery with targeted intraoperative radiotherapy for the management of ductal carcinoma in situ. ( 30589080 )
2019
13
No Ink on Ductal Carcinoma In Situ: A Single Centre Experience. ( 30591495 )
2019
14
National consensus recommendations on patient-centered care for ductal carcinoma in situ. ( 30627960 )
2019
15
BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ. ( 30652428 )
2019
16
Is it possible to predict underestimation in ductal carcinoma in situ of the breast? Yes, using a simple score! ( 30665684 )
2019
17
A single-center study on total mastectomy versus skin-sparing mastectomy in case of pure ductal carcinoma in situ of the breast. ( 30683448 )
2019
18
Accuracy of Breast MRI Compared to MG in the Preoperative Detection and Measurement of Pure Ductal Carcinoma In Situ: A Methodological Issue. ( 30711410 )
2019
19
Qualitative Radiogenomics: Association Between BI-RADS Calcification Descriptors and Recurrence Risk as Assessed by the Oncotype DX Ductal Carcinoma In Situ Score. ( 30714832 )
2019
20
Behaviour and characteristics of low-grade ductal carcinoma in situ of the breast: literature review and single centre retrospective series. ( 30734334 )
2019
21
Response to: Accuracy of Breast MRI Compared to MG in the Preoperative Detection and Measurement of Pure Ductal Carcinoma In Situ: A Methodological Issue. ( 30737077 )
2019
22
Evaluating the relationship between ductal carcinoma in situ, calcifications, and margin status in patients undergoing breast conserving surgery. ( 30742316 )
2019
23
Ductal carcinoma in situ of the breast: an update for the pathologist in the era of individualized risk assessment and tailored therapies. ( 30760859 )
2019
24
An Uncommon Pairing of common Tumors: Case Report of Ductal Carcinoma in situ Within Fibroadenoma. ( 30766763 )
2019
25
Twenty-Five Year Trends in the Incidence of Ductal Carcinoma in Situ in US Women. ( 30772444 )
2019
26
Sentinel lymph node biopsy in microinvasive ductal carcinoma in situ. ( 30791092 )
2019
27
Magnetic resonance imaging of the breast: role in the evaluation of ductal carcinoma in situ. ( 30804615 )
2019
28
Preoperative Breast Magnetic Resonance Imaging in Women With Local Ductal Carcinoma in Situ to Optimize Surgical Outcomes: Results From the Randomized Phase III Trial IRCIS. ( 30811290 )
2019
29
Impact of Epithelial-Stromal Interactions on Peritumoral Fibroblasts in Ductal Carcinoma in Situ. ( 30816935 )
2019
30
Management of Ductal Carcinoma In Situ (DCIS) of the Breast: Present Approaches and Future Directions. ( 30834994 )
2019
31
Effect of preoperative injection of superparamagnetic iron oxide particles on rates of sentinel lymph node dissection in women undergoing surgery for ductal carcinoma in situ (SentiNot study). ( 30839104 )
2019
32
Accuracy of Distinguishing Atypical Ductal Hyperplasia From Ductal Carcinoma In Situ With Convolutional Neural Network-Based Machine Learning Approach Using Mammographic Image Data. ( 30860901 )
2019
33
The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS). ( 30862637 )
2019
34
Surgery and adjuvant radiotherapy for unilateral ductal carcinoma in situ (DCIS) in women aged over 70 years: A population based cohort study. ( 30878169 )
2019
35
Granulomatous lobular mastitis associated with ductal carcinoma in situ of the breast. ( 30899513 )
2019
36
Genomic Assays to Assess Local Recurrence Risk and Predict Radiation Therapy Benefit in Patients With Ductal Carcinoma In Situ. ( 30900551 )
2019
37
Sentinel node mapping and ductal carcinoma in situ. ( 30903404 )
2019
38
AKT1low quiescent cancer cells in ductal carcinoma in situ of the breast. ( 30911675 )
2019
39
Progression of ductal carcinoma in situ to invasive breast cancer: comparative genomic sequencing. ( 30284611 )
2019
40
Comparison of Clinical and Pathologic Characteristics of Ductal Carcinoma in Situ Detected on Mammography versus Ultrasound Only in Asymptomatic Patients. ( 30322671 )
2019
41
Evaluating the Rate of Upgrade to Invasive Breast Cancer and/or Ductal Carcinoma In Situ Following a Core Biopsy Diagnosis of Non-classic Lobular Carcinoma In Situ. ( 30362065 )
2019
42
Thioredoxin-interacting protein is an independent risk stratifier for breast ductal carcinoma in situ. ( 29955142 )
2018
43
The PPARI^ agonist efatutazone delays invasive progression and induces differentiation of ductal carcinoma in situ. ( 29350308 )
2018
44
Glucocorticoids promote transition of ductal carcinoma in situ to invasive ductal carcinoma by inducing myoepithelial cell apoptosis. ( 29973218 )
2018
45
Oncoplastic breast surgery for the management of ductal carcinoma in situ (DCIS): is it oncologically safe? A retrospective cohort analysis. ( 29759643 )
2018
46
Prediction of Occult Invasive Disease in Ductal Carcinoma in Situ Using Deep Learning Features. ( 29398498 )
2018
47
Magnetic resonance imaging findings of high-grade ductal carcinoma in situ of the male breast: A case report. ( 29977557 )
2018
48
Controversies Regarding the Diagnosis and Management of Ductal Carcinoma In Situ. ( 29428007 )
2018
49
Tamoxifen therapy improves overall survival in luminal A subtype of ductal carcinoma in situ: a study based on nationwide Korean Breast Cancer Registry database. ( 29383628 )
2018
50
The association between post-diagnosis health behaviors and long-term quality of life in survivors of ductal carcinoma in situ: a population-based longitudinal cohort study. ( 29417425 )
2018
Sources

Variations for Ductal Carcinoma in Situ

About this section

Cosmic variations for Ductal Carcinoma in Situ:

9 (show all 44)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6005476 ZFHX3 breast,NS,carcinoma in situ,ductal carcinoma in situ c.2403A>T p.K801N 16:72957743-72957743 0
2 COSM10701 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.824G>T p.C275F 17:7673796-7673796 0
3 COSM10867 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.797G>A p.G266E 17:7673823-7673823 0
4 COSM10656 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.742C>T p.R248W 17:7674221-7674221 0
5 COSM44415 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.711G>C p.M237I 17:7674252-7674252 0
6 COSM44737 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.860A>G p.E287G 17:7673760-7673760 0
7 COSM6932 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.733G>A p.G245S 17:7674230-7674230 0
8 COSM10662 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.743G>A p.R248Q 17:7674220-7674220 0
9 COSM10779 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.818G>T p.R273L 17:7673802-7673802 0
10 COSM43559 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.517G>T p.V173L 17:7675095-7675095 0
11 COSM43714 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.836G>A p.G279E 17:7673784-7673784 0
12 COSM44901 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.532C>G p.H178D 17:7675080-7675080 0
13 COSM10660 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.818G>A p.R273H 17:7673802-7673802 0
14 COSM43814 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.587G>C p.R196P 17:7674944-7674944 0
15 COSM11089 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.584T>C p.I195T 17:7674947-7674947 0
16 COSM6906973 SMARCA4 breast,NS,carcinoma in situ,ductal carcinoma in situ c.1111G>T p.E371* 19:10987917-10987917 0
17 COSM6906974 PPP2R1A breast,NS,carcinoma in situ,ductal carcinoma in situ c.510C>A p.F170L 19:52212692-52212692 0
18 COSM760 PIK3CA breast,NS,carcinoma in situ,ductal carcinoma in situ c.1624G>A p.E542K 3:179218294-179218294 0
19 COSM12458 PIK3CA breast,NS,carcinoma in situ,ductal carcinoma in situ c.1634A>C p.E545A 3:179218304-179218304 0
20 COSM775 PIK3CA breast,NS,carcinoma in situ,ductal carcinoma in situ c.3140A>G p.H1047R 3:179234297-179234297 0
21 COSM776 PIK3CA breast,NS,carcinoma in situ,ductal carcinoma in situ c.3140A>T p.H1047L 3:179234297-179234297 0
22 COSM763 PIK3CA breast,NS,carcinoma in situ,ductal carcinoma in situ c.1633G>A p.E545K 3:179218303-179218303 0
23 COSM774 PIK3CA breast,NS,carcinoma in situ,ductal carcinoma in situ c.3139C>T p.H1047Y 3:179234296-179234296 0
24 COSM754 PIK3CA breast,NS,carcinoma in situ,ductal carcinoma in situ c.1035T>A p.N345K 3:179203765-179203765 0
25 COSM580 NRAS breast,NS,carcinoma in situ,ductal carcinoma in situ c.181C>A p.Q61K 1:114713909-114713909 0
26 COSM565 NRAS breast,NS,carcinoma in situ,ductal carcinoma in situ c.35G>C p.G12A 1:114716126-114716126 0
27 COSM6057047 NOTCH1 breast,NS,carcinoma in situ,ductal carcinoma in situ c.7372C>T p.P2458S 9:136496367-136496367 0
28 COSM6005481 MAP2K2 breast,NS,carcinoma in situ,ductal carcinoma in situ c.931G>T p.D311Y 19:4097332-4097332 0
29 COSM521 KRAS breast,NS,carcinoma in situ,ductal carcinoma in situ c.35G>A p.G12D 12:25245350-25245350 0
30 COSM532 KRAS breast,NS,carcinoma in situ,ductal carcinoma in situ c.38G>A p.G13D 12:25245347-25245347 0
31 COSM516 KRAS breast,NS,carcinoma in situ,ductal carcinoma in situ c.34G>T p.G12C 12:25245351-25245351 0
32 COSM520 KRAS breast,NS,carcinoma in situ,ductal carcinoma in situ c.35G>T p.G12V 12:25245350-25245350 0
33 COSM1179671 KMT2C breast,NS,carcinoma in situ,ductal carcinoma in situ c.925C>T p.P309S 7:152273792-152273792 0
34 COSM4595028 KMT2C breast,NS,carcinoma in situ,ductal carcinoma in situ c.2681G>A p.R894Q 7:152235905-152235905 0
35 COSM6057048 HRAS breast,NS,carcinoma in situ,ductal carcinoma in situ c.148A>G p.T50A 11:533908-533908 0
36 COSM6906971 H3F3A breast,NS,carcinoma in situ,ductal carcinoma in situ c.218G>A p.R73Q 1:226065745-226065745 0
37 COSM48358 ERBB2 breast,NS,carcinoma in situ,ductal carcinoma in situ c.929C>T p.S310F 17:39711955-39711955 0
38 COSM14060 ERBB2 breast,NS,carcinoma in situ,ductal carcinoma in situ c.2264T>C p.L755S 17:39723967-39723967 0
39 COSM19786 CDH1 breast,NS,carcinoma in situ,ductal carcinoma in situ c.779C>T p.P260L 16:68810288-68810288 0
40 COSM6057049 AKT1 breast,NS,carcinoma in situ,ductal carcinoma in situ c.61A>G p.T21A 14:104780202-104780202 0
41 COSM33765 AKT1 breast,NS,carcinoma in situ,ductal carcinoma in situ c.49G>A p.E17K 14:104780214-104780214 0
42 COSM5174142 breast,NS,carcinoma in situ,ductal carcinoma in situ c.884C>T p.S295F 17:39711955-39711955 0
43 COSM6906972 breast,NS,carcinoma in situ,ductal carcinoma in situ c.1111G>T p.E371* 19:10987917-10987917 0
44 COSM6964823 breast,NS,carcinoma in situ,ductal carcinoma in situ c.659C>T p.T220M 1:39897898-39897898 0
Sources

Expression for Ductal Carcinoma in Situ

About this section
Search GEO for disease gene expression data for Ductal Carcinoma in Situ.
Sources

Pathways for Ductal Carcinoma in Situ

About this section

Pathways related to Ductal Carcinoma in Situ according to GeneCards Suite gene sharing:

(show top 50) (show all 68)
# Super pathways Score Top Affiliating Genes
1
ERK Signaling 65
Show member pathways
 13.9 AKT1 BRCA1 CCND1 CDH1 EGFR ERBB2
2
GPCR Pathway 65
Show member pathways
 13.75 AKT1 BRCA1 BRCA2 CCND1 EGFR ERBB2
3
Cytokine Signaling in Immune system 67
Show member pathways
 13.39 AKT1 CCND1 EGFR ERBB2 MUC1 PTGS2
4
PI3K-Akt signaling pathway 38
Show member pathways
 13.01 AKT1 BRCA1 CCND1 EGFR ERBB2 PTGS2
5
Endometrial cancer 38
Show member pathways
 12.78 AKT1 AR BRCA2 CCND1 CDH1 EGFR
6
Development HGF signaling pathway 23
Show member pathways
 12.74 AKT1 CDH1 ERBB2 ESR1 PTGS2 TP53
7
Chks in Checkpoint Regulation 65
Show member pathways
 12.73 BRCA1 BRCA2 CCND1 ESR1 TP53
8
ErbB signaling pathway 1 38
Show member pathways
 12.63 AKT1 CCND1 EGFR ERBB2 TP53
9
Pathways in cancer 38
12.58 AKT1 AR BRCA2 CCND1 CDH1 EGFR
10
Glioma 38
Show member pathways
 12.51 AKT1 BRCA1 BRCA2 CCND1 CDH1 EGFR
11
MicroRNAs in cancer 38
12.5 BRCA1 CCND1 EGFR ERBB2 PTGS2 TP53
12
Apoptosis Pathway 73
Show member pathways
 12.46 AKT1 EGFR ERBB2 TP53
13
WNT Signaling 65
12.46 AKT1 CCND1 CDH1 PTGS2 TP53
14
Development VEGF signaling via VEGFR2 - generic cascades 23
Show member pathways
 12.42 AKT1 BRCA1 ESR1 PTGS2
15
Gastric cancer 38
Show member pathways
 12.32 AKT1 BRCA1 BRCA2 CCND1 CDH1 EGFR
16
Development Ligand-independent activation of ESR1 and ESR2 23
Show member pathways
 12.31 AKT1 CCND1 EGFR ERBB2 ESR1 PTGS2
17
p53 Signaling 65
Show member pathways
 12.29 AKT1 BRCA1 CCND1 TP53
18
Cell cycle Role of SCF complex in cell cycle regulation 23
Show member pathways
 12.26 BRCA1 CCND1 ESR1 PGR
19
Proteoglycans in cancer 38
12.24 AKT1 CCND1 EGFR ERBB2 ESR1 TP53
20
MAPK Signaling: Mitogen Stimulation Pathway 66
Show member pathways
 12.23 AKT1 CCND1 EGFR ERBB2 TP53
21
AKT Signaling Pathway 68
12.16 AKT1 CCND1 EGFR ERBB2 TP53
22
Transcription Androgen Receptor nuclear signaling 23
Show member pathways
 12.12 AKT1 AR CCND1 EGFR ERBB2
23
Signaling by PTK6 67
Show member pathways
 12.11 AKT1 CCND1 EGFR ERBB2
24
MAPK Pathway 73
Show member pathways
 12.08 AKT1 EGFR ERBB2 TP53
25
Spinal Cord Injury 1
12.06 CCND1 EGFR PTGS2 TP53
26
Colorectal Cancer Metastasis 65
12.06 AKT1 CCND1 CDH1 EGFR PTGS2 TP53
27
Cell cycle Cell cycle (generic schema) 23
Show member pathways
 12.03 AKT1 CCND1 CDH1 PTGS2 TP53
28
Thyroid hormone signaling pathway 38
12.03 AKT1 CCND1 ESR1 TP53
29
DNA Damage Response (only ATM dependent) 1
12.02 AKT1 CCND1 ERBB2 TP53
30
Glioblastoma Multiforme 65
12 AKT1 CCND1 EGFR TP53
31
Interleukin-4 and 13 signaling 67
11.99 AKT1 CCND1 MUC1 PTGS2 TP53
32
Signaling by ERBB4 67
Show member pathways
 11.98 EGFR ERBB2 ESR1 PGR
33
Small cell lung cancer 38
11.91 AKT1 CCND1 PTGS2 TP53
34
Nuclear Receptor transcription pathway 67
Show member pathways
 11.87 AR ESR1 PGR
35
Glucocorticoid receptor regulatory network 1
11.84 AKT1 KRT14 KRT5 TP53
36
BRCA1 Pathway 65
Show member pathways
 11.83 BRCA1 BRCA2 TP53
37
Androgen receptor signaling pathway 1
11.83 AKT1 AR BRCA1 CCND1 EGFR
38
Regulation of Wnt-mediated beta catenin signaling and target gene transcription 1
11.81 AR CCND1 CDH1
39
Regulation of nuclear SMAD2/3 signaling 1
11.79 AKT1 AR ESR1
40
Platinum drug resistance 38
11.78 AKT1 BRCA1 ERBB2 TP53
41
Adherens junction 38
11.76 CDH1 EGFR ERBB2
42
Transcription Ligand-dependent activation of the ESR1/SP pathway 23
Show member pathways
 11.75 CCND1 EGFR ESR1
43
Association Between Physico-Chemical Features and Toxicity Associated Pathways 1
11.73 AKT1 EGFR ERBB2
44
Pathways Affected in Adenoid Cystic Carcinoma 1
11.72 AKT1 BRCA1 ERBB2 TP53
45
Regulation of Telomerase 1
11.71 AKT1 CCND1 EGFR ESR1
46
Central carbon metabolism in cancer 38
11.7 AKT1 EGFR ERBB2 TP53
47
IL-2 Gene Expression in Activated and Quiescent T-Cells 65
Show member pathways
 11.67 AKT1 CCND1 EGFR ERBB2
48
Bladder cancer 38 1
11.67 CCND1 CDH1 EGFR ERBB2 TP53
49
Validated targets of C-MYC transcriptional repression 1
11.66 BRCA1 CCND1 ERBB2 S100A7
50
Copper homeostasis 1
11.63 AKT1 CCND1 TP53
Sources

GO Terms for Ductal Carcinoma in Situ

About this section

Cellular components related to Ductal Carcinoma in Situ according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.89 AKT1 AR BRCA1 BRCA2 CCND1 CDH1
2 nuclear chromatin GO:0000790 9.56 AR ESR1 MUC1 TP53
3 protein-containing complex GO:0032991 9.23 AKT1 AR BRCA1 BRCA2 EGFR ESR1
4 nucleus GO:0005634 10.06 AKT1 AR BRCA1 BRCA2 CCND1 EGFR

Biological processes related to Ductal Carcinoma in Situ according to GeneCards Suite gene sharing:

(show all 37)
# Name GO ID Score Top Affiliating Genes
1 protein deubiquitination GO:0016579 9.97 AR BRCA1 ESR1 TP53
2 positive regulation of protein phosphorylation GO:0001934 9.9 AKT1 CCND1 EGFR ERBB2
3 cytokine-mediated signaling pathway GO:0019221 9.89 AKT1 CCND1 MUC1 PTGS2 TP53
4 transcription initiation from RNA polymerase II promoter GO:0006367 9.88 AR CCND1 ESR1 PGR
5 positive regulation of gene expression GO:0010628 9.88 AKT1 AR BRCA1 ERBB2 PIP TP53
6 cell proliferation GO:0008283 9.85 AKT1 AR BRCA2 EGFR ERBB2 TP53
7 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.84 AKT1 EGFR PTGS2
8 positive regulation of cell growth GO:0030307 9.84 AKT1 EGFR ERBB2
9 cellular response to mechanical stimulus GO:0071260 9.82 AKT1 EGFR PTGS2
10 response to estrogen GO:0043627 9.81 BRCA1 CCND1 ESR1
11 cellular response to growth factor stimulus GO:0071363 9.79 AKT1 EGFR ERBB2
12 positive regulation of smooth muscle cell proliferation GO:0048661 9.78 AKT1 EGFR PTGS2
13 steroid hormone mediated signaling pathway GO:0043401 9.76 AR ESR1 PGR
14 epidermis development GO:0008544 9.76 EGFR KRT14 KRT5 S100A7
15 positive regulation of transcription, DNA-templated GO:0045893 9.76 AKT1 AR BRCA1 BRCA2 CDH1 EGFR
16 cellular response to epidermal growth factor stimulus GO:0071364 9.73 AKT1 EGFR ERBB2
17 response to organic substance GO:0010033 9.73 AKT1 CCND1 CDH1 PTGS2
18 hemidesmosome assembly GO:0031581 9.67 KRT14 KRT5
19 Leydig cell differentiation GO:0033327 9.66 AR CCND1
20 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.65 ESR1 TP53
21 positive regulation of vasoconstriction GO:0045907 9.65 AKT1 EGFR PTGS2
22 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.64 EGFR TP53
23 mitotic G1 DNA damage checkpoint GO:0031571 9.63 CCND1 TP53
24 prostate gland growth GO:0060736 9.62 AR CYP19A1
25 negative regulation of ERBB signaling pathway GO:1901185 9.59 EGFR ERBB2
26 cellular response to indole-3-methanol GO:0071681 9.57 BRCA1 CDH1
27 response to estradiol GO:0032355 9.56 CCND1 EGFR ESR1 PTGS2
28 chordate embryonic development GO:0043009 9.55 BRCA1 BRCA2
29 morphogenesis of an epithelial fold GO:0060571 9.54 AR EGFR
30 mammary gland development GO:0030879 9.52 CYP19A1 PGR
31 tertiary branching involved in mammary gland duct morphogenesis GO:0060748 9.51 AR PGR
32 mammary gland alveolus development GO:0060749 9.5 AR CCND1 ESR1
33 positive regulation of transcription by RNA polymerase III GO:0045945 9.35 AR
34 response to UV-A GO:0070141 9.13 AKT1 CCND1 EGFR
35 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 8.92 BRCA1 BRCA2 MUC1 TP53
36 positive regulation of transcription by RNA polymerase II GO:0045944 10.17 AKT1 AR BRCA1 EGFR ESR1 PGR
37 cellular response to DNA damage stimulus GO:0006974 10.04 AKT1 BRCA1 BRCA2 CCND1 TP53

Molecular functions related to Ductal Carcinoma in Situ according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 zinc ion binding GO:0008270 9.97 AR BRCA1 ESR1 PGR S100A7 TP53
2 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.88 AR ESR1 MUC1 PGR TP53
3 protein kinase binding GO:0019901 9.85 AKT1 CCND1 EGFR ESR1 TP53
4 beta-catenin binding GO:0008013 9.71 AR CDH1 ESR1
5 protein phosphatase binding GO:0019903 9.7 EGFR ERBB2 TP53
6 ATPase binding GO:0051117 9.69 AR ESR1 PGR
7 identical protein binding GO:0042802 9.65 AKT1 BRCA1 BRCA2 CDH1 CLDN7 EGFR
8 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.61 EGFR ERBB2 ESR1
9 steroid hormone receptor activity GO:0003707 9.58 AR ESR1 PGR
10 nuclear receptor activity GO:0004879 9.54 AR ESR1 PGR
11 steroid binding GO:0005496 9.5 AR ESR1 PGR
12 nitric-oxide synthase regulator activity GO:0030235 9.33 AKT1 EGFR ESR1
13 enzyme binding GO:0019899 9.28 AKT1 AR BRCA1 CCND1 EGFR ESR1
14 protein binding GO:0005515 10.23 AKT1 AR BRCA1 BRCA2 CCND1 CDH1
Sources

Sources for Ductal Carcinoma in Situ

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....